查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1775334

基因组编辑市场 - 预测 2025-2030

Genome Editing Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

基因组编辑市场预计将从 2025 年的 40.87 亿美元成长到 2030 年的 80.18 亿美元，复合年增长率为 14.43%。

基因组编辑是一种改变生物体DNA的技术，在农业、医疗保健和科研领域至关重要。其应用包括提高作物产量、诊断和治疗疾病以及促进科学发现。受癌症和遗传疾病发病率上升、投资增加以及政府扶持政策的推动，全球基因组编辑市场正经历显着增长。本摘要专为行业专业人士量身定制，重点关注关键市场驱动因素以及基于2024年及未来市场发展预测的区域趋势。

市场驱动因素

  • 癌症和遗传疾病发生率不断上升

全球癌症和遗传疾病的增加持续推动对基因组编辑解决方案的需求。国际癌症研究机构 (IARC) 预测癌症患者数量将大幅增加，其中欧洲预计将从 2020 年的 439.8 万人增长到 2040 年的 532.3 万人（增长 21%），北美同期将从 255.7 万人增长到 352.5 万人（增长 38%）。预计到 2040 年，亚洲的癌症患者数量将激增 59% 以上。这些令人担忧的趋势凸显了对创新疗法的迫切需求，将基因组编辑定位为开发标靶治疗的关键工具。新型遗传疾病的发现进一步扩大了这种需求，随着研究人员利用基因组编辑来治疗复杂的病理，推动了市场扩张。

  • 增加投资和研究

基因组编辑技术在解决农业和医疗保健领域挑战的潜力推动了其投资的激增。世界各国政府正积极支持这些进步。例如，英国政府将继续简化法规，以促进2024年后农业基因组编辑技术的研发，旨在提高作物产量并确保基因组编辑产品的安全上市。同样，中国政府也优先发展基于CRISPR技术的创新，以加强粮食安全，并投入了大量的前期资金。这些努力，加上全球研究计画的配合，预计将透过促进创新和扩大基因组编辑技术的应用，进一步加速市场成长。

地理视角

北美市场领导地位

由于在研发方面大力投入，北美在全球基因组编辑市场占据主导地位。该地区强大的基础设施，加上其对日益增长的癌症和遗传疾病病例的重视，巩固了其主导地位。学术机构、生技公司和政府机构之间的合作不断推动基因组编辑应用，确保了北美在市场上的主导地位。

亚太地区快速成长

受医疗支出成长以及遗传疾病和癌症盛行率上升的推动，亚太地区预计将迎来显着的市场成长。中国在政府扶持计画的支持下，广泛应用CRISPR技术，是推动这项成长的关键因素。该地区致力于透过基因组编辑改善医疗保健成果和农业生产力，使其成为全球市场的重要成长中心。

基因组编辑市场正呈现强劲成长势头，这得益于癌症和遗传疾病先进疗法需求的不断增长、全球投资的不断增加以及政府政策的支持。北美凭藉着良好的投资环境引领产业发展，而亚太地区正逐渐成为高成长地区，尤其是在中国CRISPR技术取得进展的带动下。这些趋势凸显了基因组编辑的变革潜力，使其成为2040年产业创新和投资的焦点。

本报告的主要优点

  • 深刻分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场。
  • 竞争格局：了解全球主要企业所采用的策略策略，并了解正确策略带来的潜在市场渗透。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响市场的未来发展。
  • 可行的建议：利用洞察力进行策略决策，在动态环境中开闢新的业务流和收益。
  • 适用范围广：对于新兴企业、科学研究机构、顾问公司、中小企业、大型企业都有利且划算。

它有什么用途？

产业和市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

研究范围

  • 2022 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 各细分市场和地区（包括国家）的收益成长和预测分析

公司简介

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 研究范围
  • 市场区隔

第三章 商业景气

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

第五章 基因组编辑市场（依技术类型）

  • 介绍
  • CRISPR
  • 塔伦
  • ZFN
  • 其他的

第六章 基因组编辑市场（依应用）

  • 介绍
  • 细胞株工程
  • 动物基因工程
  • 植物基因工程

第七章 基因组编辑市场（依最终用户）

  • 介绍
  • 学术研究所
  • 生物技术和製药公司
  • 合约研究组织

第八章 基因组编辑市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 其他的

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争仪錶板

第十章 公司简介

  • Thermo Fisher Scientific Inc.
  • Merck & Co., Inc.
  • Horizon Discovery Group plc
  • GenScript
  • Sangamo Therapeutics, Inc.
  • Danaher Corporation
  • Lonza Group AG
  • BEX Co., LTD.
  • OriGene Technologies, Inc.
  • CRISPR Therapeutics

第十一章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061612981

The genome editing market is expected to grow from USD 4.087 billion in 2025 to USD 8.018 billion in 2030, at a CAGR of 14.43%.

Genome editing, a transformative technique for altering an organism's DNA, is pivotal in agriculture, healthcare, and research. Its applications include enhancing crop yields, diagnosing and treating diseases, and advancing scientific discovery. The global genome editing market has experienced significant growth driven by increasing incidences of cancer and genetic disorders, rising investments, and supportive government policies. This summary, tailored for industry experts, focuses on key market drivers and geographical trends based on developments from 2024 onward, excluding earlier data as requested.

Market Drivers

  • Rising Prevalence of Cancer and Genetic Disorders

The global increase in cancer and genetic disorders continues to propel demand for genome editing solutions. The International Agency for Research on Cancer (IARC) projects a significant rise in cancer cases, with Europe expecting an increase from 4.398 million in 2020 to 5.323 million by 2040 (a 21% rise) and North America anticipating growth from 2.557 million to 3.525 million (a 38% increase) over the same period. In Asia, cancer cases are forecasted to surge by over 59% by 2040. These alarming trends underscore the urgent need for innovative treatments, positioning genome editing as a critical tool for developing targeted therapies. The identification of new genetic disorders further amplifies this demand, as researchers leverage genome editing to address complex conditions, driving market expansion.

  • Increased Investments and Research

Investments in genome editing have surged, fueled by its potential to address agricultural and healthcare challenges. Governments worldwide are actively supporting these advancements. For instance, in 2024 and beyond, the UK government has continued to streamline regulations to facilitate research and development in genome editing for agriculture, aiming to enhance crop productivity and ensure safe market entry for genome-edited products. Similarly, China's government has prioritized CRISPR-based innovations to bolster food security, building on significant prior investments. These efforts are complemented by global research initiatives, which are expected to further accelerate market growth by fostering innovation and expanding applications of genome editing technologies.

Geographical Outlook

North America's Market Leadership

North America is poised to maintain a dominant share of the global genome editing market, driven by substantial investments in research and development. The region's robust infrastructure, coupled with a strong focus on addressing rising cancer and genetic disorder cases, supports its leadership position. Collaborative efforts between academic institutions, biotech firms, and government agencies continue to advance genome editing applications, ensuring North America's prominence in the market.

Asia Pacific's Rapid Growth

The Asia Pacific region is expected to experience significant market growth, propelled by increasing healthcare expenditures and the rising prevalence of genetic disorders and cancer. China's extensive use of CRISPR technology, supported by government-backed initiatives, is a key driver of this growth. The region's focus on improving healthcare outcomes and agricultural productivity through genome editing positions it as a critical growth hub in the global market.

The genome editing market is on a robust growth trajectory, driven by the escalating need for advanced treatments for cancer and genetic disorders, increased global investments, and supportive government policies. North America leads due to its investment landscape, while the Asia Pacific region is emerging as a high-growth area, particularly with China's advancements in CRISPR. These trends highlight genome editing's transformative potential, making it a focal point for industry innovation and investment through 2040.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries

Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Genome Editing Market Segmentation

By Technology Type

  • CRISPR
  • TALEN
  • ZFN
  • Others

By Application

  • Cell Line Engineering
  • Animal Genetic Engineering
  • Plant Genetic Engineering

By End-User

  • Academic & Research Institutes
  • Biotechnology & Pharmaceutical Company
  • Contract Research Organization

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • UK
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GENOME EDITING MARKET BY TECHNOLOGY TYPE

  • 5.1. Introduction
  • 5.2. CRISPR
  • 5.3. TALEN
  • 5.4. ZFN
  • 5.5. Others

6. GENOME EDITING MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Cell Line Engineering
  • 6.3. Animal Genetic Engineering
  • 6.4. Plant Genetic Engineering

7. GENOME EDITING MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Academic & Research Institutes
  • 7.3. Biotechnology & Pharmaceutical Company
  • 7.4. Contract Research Organization

8. GENOME EDITING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Thermo Fisher Scientific Inc.
  • 10.2. Merck & Co., Inc.
  • 10.3. Horizon Discovery Group plc
  • 10.4. GenScript
  • 10.5. Sangamo Therapeutics, Inc.
  • 10.6. Danaher Corporation
  • 10.7. Lonza Group AG
  • 10.8. BEX Co., LTD.
  • 10.9. OriGene Technologies, Inc.
  • 10.10. CRISPR Therapeutics

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key benefits for the stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations